The cost effectiveness of preventing cardiovascular diseases

Canadian Journal of Cardiology

Volumn 15, Issue SUPPL. G, 1999, Pages

  Grover, Steven A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH EDUCATION; HUMAN; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; HEALTH EDUCATION; HUMANS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS;

EID: 0033250999     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Heart Disease and Stroke in Canada. Ottawa: Heart and Stroke Foundation of Canada, 1997.
2. Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals: Canada, 2nd edn. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997.
3. Goldman L, Garber AM, Grover SA, Hlatky MA. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996;27:1020-30.
4. Drummond MF, Heyse J, Cook J, McGuire A. Selection of end points in economic evaluations of coronary-heart-disease interventions. Med Decis Making 1993;13:184-90.
5. Charlson ME, Alderman M, Melcher L. Absenteeism and labelling in hypertensive subjects. Prevention of an adverse impact in those at high risk. Am J Med 1982;73:165-70.
6. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 1978;299:741-4.
7. Havas S, Reisman J, Hsu L, Koumjian L. Does cholesterol screening result in negative labeling effect? Results of the Massachusetts Model Systems for Blood Cholesterol Screening Project. Arch Intern Med 1991;151:113-9.
8. Irvine MJ, Logan AG. Is knowing your cholesterol number harmful? J Clin Epidemiol 1994;47:131-45.
9. Jachuck SJ, Brierley H, Jachuck S, Willcox PM. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract 1982;32:103-5.
10. Brett AS. Psychologic effects of the diagnosis and treatment of hypercholesterolemia: Lessons from case studies. Am J Med 1991;91:642-7.
11. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93:1796-802.
12. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600.
13. Grover SA, Abrahamowicz M, Joseph L, Brewer C, Coupal L, Suissa S. The benefits of treating hyperlipidemia to prevent coronary heart disease. Estimating changes in life expectancy and moribidity. JAMA 1992;267:816-22.
14. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of raising HDL-C. JAMA 1995;273:1032-8.
15. Littenberg B, Garber AM, Sox HC Jr. Screening for hypertension. Ann Intern Med 1990;112:192-202.
16. Weinstein MC, Stason WB. Hypertension: A Policy Perspective. Cambridge: Harvard University Press, 1976.
17. Edelson JT, Weinstein MC, Tosteson ANA, Williams L, Lee TH, Goldman L. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990;263:407-13.
18. Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. JAMA 1989;261:75-9.
19. Oster G, Huse DM, Delea TE, Colditz GA. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. JAMA 1986;256:1315-8.
20. Tsevat J. Impact and cost-effectiveness of smoking interventions. Am J Med 1992;93(1A):43S-7S.
21. Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 1993;22:1697-702.
22. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 1988;260:945-50.
23. O'Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80:234-44.
24. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990;132:612-28.
25. Oldridge N, Furlong W, Feeny D, et al. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. Am J Cardiol 1993;72:154-61.
26. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: A cross-national study. JAMA 1998;279:1458-62.